$2.25
8.16% today
Nasdaq, Apr 03, 06:20 pm CET
ISIN
US7574681034
Symbol
RDHL
Sector
Industry

RedHill Biopharma Ltd. Sponsored ADR Stock price

$2.45
-0.81 24.85% 1M
-5.59 69.53% 6M
-3.76 60.55% YTD
-10.80 81.51% 1Y
-2,577.55 99.91% 3Y
-5,177.55 99.95% 5Y
-14,687.55 99.98% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.10 3.92%
ISIN
US7574681034
Symbol
RDHL
Sector
Industry

Key metrics

Market capitalization $3.12m
Enterprise Value $-10.75m
EV/FCF (TTM) EV/FCF 0.41
EV/Sales (TTM) EV/Sales -0.30
P/S ratio (TTM) P/S ratio 0.09
Short interest 4.11%

Is RedHill Biopharma Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast RedHill Biopharma Ltd. Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast RedHill Biopharma Ltd. Sponsored ADR:

Buy
100%

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '23
+/-
%
6.51 6.51
89% 89%
100%
- Direct Costs 3.45 3.45
90% 90%
53%
3.06 3.06
89% 89%
47%
- Selling and Administrative Expenses 29 29
48% 48%
444%
- Research and Development Expense 3.52 3.52
51% 51%
54%
-29 -29
15% 15%
-451%
- Depreciation and Amortization 1.98 1.98
76% 76%
30%
EBIT (Operating Income) EBIT -31 -31
27% 27%
-482%
Net Profit 24 24
133% 133%
366%

In millions USD.

Don't miss a Thing! We will send you all news about RedHill Biopharma Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral
PRNewsWire
16 days ago
RedHill plans to submit UK MAA 1  for Talicia for H. pylori infection, using MHRA's 2  new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed by ACG 3  Clinical Guideline as a first-line option, Talicia is the leading branded H.
Neutral
PRNewsWire
22 days ago
The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will correlate mucosal healing with MAP2 infection eradication utilizing novel endpoints and imaging, pending Type C discussions on path to FDA approval, with FDA guidance expected in Q2/25 -- Patent protected until 2041, RHB-204 is a next generat...
Neutral
PRNewsWire
about one month ago
Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent out-licensing of RHB-102 [1] to Hyloris (Euronext Brussels: HYL) in a potential $60 million plus royalties deal Initiation of the Bayer-funded Phase 2 clinical study of opaganib [2] in combination with Bayer's (ETR: BAYN) darolutamide in advanced...
More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Dror Ben-Asher
Founded 2009
Website www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today